NDABUCCALGUM, CHEWING
Approved
Jun 1992
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NICORETTE (MINT) is a nicotine polacrilex chewing gum formulation approved in 1992 for smoking cessation. It works as a cholinergic nicotinic agonist, delivering nicotine through the buccal mucosa to reduce cravings and withdrawal symptoms. The product is a foundational OTC aid for tobacco dependence treatment.
LOE Approaching1.6 years to LOE
Mature franchise nearing patent expiry (2028) with moderate competitive pressure; brand teams face transition from growth to defense and generic transition planning.
Mechanism of Action
Pharmacologic Class:
Cholinergic Nicotinic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on NICORETTE (MINT) at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.